Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Evolus, Inc. - Common Stock (NQ:EOLS)

8.925 -0.185 (-2.03%)
Streaming Delayed Price Updated: 3:25 PM EDT, Aug 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Earnings Scheduled For March 4, 2025
 
Via Benzinga
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates
 
Via Benzinga
A Closer Look at 5 Analyst Recommendations For Evolus
 
Via Benzinga
Analyst Scoreboard: 4 Ratings For Evolus
 
Via Benzinga
Evolus: Chiseling Away At The Aesthetic Market
Via Talk Markets
Earnings Scheduled For August 5, 2025
 
Via Benzinga
A Look Ahead: Evolus's Earnings Forecast
 
Via Benzinga
What Analysts Are Saying About Evolus Stock
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Breaking Down Evolus: 8 Analysts Share Their Views
 
Via Benzinga
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
There's a lot going on for investors. 
Via The Motley Fool
Assessing Evolus: Insights From 6 Financial Analysts
 
Via Benzinga
Breaking Down Evolus: 4 Analysts Share Their Views
 
Via Benzinga
4 Analysts Have This To Say About Evolus
 
Via Benzinga
Crude Oil Down 2%; D.R. Horton Earnings Top Views
 
Via Benzinga
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
The company expects to soon expand from a single-product player to a "multi-product innovator." 
Via Investor's Business Daily
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss. 
Via Investor's Business Daily
Recap: Evolus Q4 Earnings
 
Via Benzinga
Earnings Outlook For Evolus
 
Via Benzinga
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. 
Via Investor's Business Daily
EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024
EOLS stock results show that Evolus beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.